Our data showed that nilotiniband other second- and third-generation BCR-ABL inhibitors, but notimatinib, are capable of blocking the p38α MAPK signaling pathway,which abates monocyte activation and differentiation, reduces cytokinerelease, and prevents inflammation in AML. This evidence concerns the gene ABL1 and acute myeloid leukemia.